27 results on '"Zivin, J"'
Search Results
2. Statin treatment and stroke outcome in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.
3. Atorvastatin reduces the risk of cardiovascular events in patients with carotid atherosclerosis: a secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.
4. Neuroprotection by the selective cyclooxygenase-2 inhibitor SC-236 results in improvements in behavioral deficits induced by reversible spinal cord ischemia.
5. Comparison of TNK with wild-type tissue plasminogen activator in a rabbit embolic stroke model.
6. Pharmacological effects of the spin trap agents N-t-butyl-phenylnitrone (PBN) and 2,2,6, 6-tetramethylpiperidine-N-oxyl (TEMPO) in a rabbit thromboembolic stroke model: combination studies with the thrombolytic tissue plasminogen activator.
7. Metalloproteinase inhibition reduces thrombolytic (tissue plasminogen activator)-induced hemorrhage after thromboembolic stroke.
8. Dehydroepiandrosterone sulfate is neuroprotective in a reversible spinal cord ischemia model: possible involvement of GABA(A) receptors.
9. Thrombolysis with tissue plasminogen activator alters adhesion molecule expression in the ischemic rat brain.
10. A long-half-life and fibrin-specific form of tissue plasminogen activator in rabbit models of embolic stroke and peripheral bleeding.
11. Diaspirin cross-linked hemoglobin improves neurological outcome following reversible but not irreversible CNS ischemia in rabbits.
12. Graded bioassay for demonstration of brain rescue from experimental acute ischemia in rats.
13. Guidelines for the management of patients with acute ischemic stroke. A statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association.
14. Delayed therapy of experimental ischemia with competitive N-methyl-D-aspartate antagonists in rabbits.
15. Tissue plasminogen activator cerebrovascular thrombolysis in rabbits is dependent on the rate and route of administration.
16. Cerebral hemorrhagic risk of aspirin or heparin therapy with thrombolytic treatment in rabbits.
17. Reduction of central nervous system ischemic injury in rabbits using leukocyte adhesion antibody treatment.
18. Detection of arterial emboli using Doppler ultrasound in rabbits.
19. Incidence of cerebral hemorrhage after treatment with tissue plasminogen activator or streptokinase following embolic stroke in rabbits [corrected].
20. Effects of calcium channel blockers on neurologic outcome after focal ischemia in rabbits.
21. Hemodilution with low-molecular-weight hydroxyethyl starch after experimental focal cerebral ischemia in rabbits.
22. Studies of the influence of biogenic amines on central nervous system ischemia.
23. The effect of ischemia on biogenic amine concentrations in the central nervous system.
24. Animal stroke models. They are relevant to human disease.
25. Intra-arterial versus intravenous tissue-type plasminogen activator treatment in experimental stroke.
26. Ethical standards in phase 1 trials of neuroprotective agents for stroke therapy.
27. Protein phosphorylation during ischemia.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.